Literature DB >> 23587654

Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa.

Damien Fournier1, Charlotte Richardot, Emeline Müller, Marjorie Robert-Nicoud, Catherine Llanes, Patrick Plésiat, Katy Jeannot.   

Abstract

BACKGROUND: Pseudomonas aeruginosa can become resistant to carbapenems by both intrinsic (mutation-driven) and transferable (β-lactamase-based) mechanisms. Knowledge of the prevalence of these various mechanisms is important in intensive care units (ICUs) in order to define optimal prevention and therapeutic strategies.
METHODS: A total of 109 imipenem-non-susceptible (MIC >4 mg/L) strains of P. aeruginosa were collected in June 2010 from the ICUs of 26 French public hospitals. Their resistance mechanisms were characterized by phenotypic, enzymatic, western blotting and molecular methods.
RESULTS: Single or associated imipenem resistance mechanisms were identified among the 109 strains. Seven isolates (6.4%) were found to produce a metallo-β-lactamase (one VIM-1, four VIM-2, one VIM-4 and one IMP-29). Porin OprD was lost in 94 (86.2%) strains as a result of mutations or gene disruption by various insertion sequences (ISPa1635, ISPa1328, IS911, ISPs1, IS51, IS222 and ISPa41). Thirteen other strains were shown to be regulatory mutants in which down-regulation of oprD was coupled with overexpressed efflux pumps CzcCBA (n = 1), MexXY (n = 9) and MexEF-OprN (n = 3). The lack of OprD was due to disruption of the oprD promoter by ISPsy2 in one strain and alteration of the porin signal sequence in another.
CONCLUSIONS: Imipenem resistance in ICU P. aeruginosa strains may result from multiple mechanisms involving metallo-β-lactamase gene acquisition and genetic events (mutations and ISs) inactivating oprD, turning down its expression while increasing efflux activities or preventing insertion of porin OprD in the outer membrane. This diversity of mechanisms allows P. aeruginosa, more than any other nosocomial pathogen, to rapidly adapt to carbapenems in ICUs.

Entities:  

Keywords:  Pseudomonas aeruginosa; active efflux; carbapenemases; imipenem resistance; porin OprD

Mesh:

Substances:

Year:  2013        PMID: 23587654     DOI: 10.1093/jac/dkt098

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

1.  Amino Acid Substitutions Account for Most MexS Alterations in Clinical nfxC Mutants of Pseudomonas aeruginosa.

Authors:  Charlotte Richardot; Paulo Juarez; Katy Jeannot; Isabelle Patry; Patrick Plésiat; Catherine Llanes
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  A convenient method to screen for carbapenemase-producing Pseudomonas aeruginosa.

Authors:  Damien Fournier; Pauline Garnier; Katy Jeannot; Amélie Mille; Anne-Sophie Gomez; Patrick Plésiat
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  Evaluation of FilmArray and Verigene systems for rapid identification of positive blood cultures.

Authors:  M M Bhatti; S Boonlayangoor; K G Beavis; V Tesic
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

5.  Activity spectrum of colicins produced by Shigella sonnei and genetic mechanism of colicin resistance in conspecific S. sonnei strains and Escherichia coli.

Authors:  Fatema Calcuttawala; Chellaram Hariharan; Gururaja P Pazhani; Santanu Ghosh; Thandavarayan Ramamurthy
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

6.  Detection of synergistic antimicrobial resistance mechanisms in clinical isolates of Pseudomonas aeruginosa from post-operative wound infections.

Authors:  Asad Bashir Awan; Aixin Yan; Yasra Sarwar; Peter Schierack; Aamir Ali
Journal:  Appl Microbiol Biotechnol       Date:  2021-11-19       Impact factor: 4.813

7.  Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.

Authors:  Angus M Quinn; Michael J Bottery; Harry Thompson; Ville-Petri Friman
Journal:  ISME J       Date:  2022-07-20       Impact factor: 11.217

8.  Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility.

Authors:  C Slekovec; J Robert; D Trystram; J M Delarbre; A Merens; N van der Mee-Marquet; C de Gialluly; Y Costa; J Caillon; D Hocquet; X Bertrand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-07       Impact factor: 3.267

9.  Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.

Authors:  Damien Fournier; Romain Carrière; Maxime Bour; Emilie Grisot; Pauline Triponney; Cédric Muller; Jérôme Lemoine; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

10.  Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Sophie Guénard; Cédric Muller; Laura Monlezun; Philippe Benas; Isabelle Broutin; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.